Andrew C. von Eschenbach, M.D., is chairman of the Manhattan Institute's Project FDA. From September of 2005 to January 2009 he served as commissioner of the U.S. Food and Drug Administration where he championed an agenda to modernize the FDA. Dr. von Eschenbach joined FDA after serving for four years as director of the National Cancer Institute (NCI) at the National Institutes of Health where he set an ambitious goal to eliminate the suffering and death due to cancer by rapid acceleration and integration of the discovery-development-delivery continuum.

Dennis A. Ausiello, M.D., is the Jackson Professor of Clinical Medicine at Harvard Medical School, and Chief of Medicine at Massachusetts General Hospital (MGH). He is also a Director of Pfizer, Inc. He has published numerous articles, book chapters, and textbooks and served as the co-editor of Cecil's Textbook of Medicine, in it's 22nd and 23rd. Dr. Ausiello is particularly interested in the training of inquisitive physicians and translational investigators, and is the architect and director of the Harvard initiative in Patient-Associated Science: Training, Education, Understanding, and Research (PASTEUR), a program designed to introduce students to patient-oriented research and to cultivate the development of the next generation of reflective physician-scientists.

Arthur Daemmrich, Ph.D., is an assistant professor in the Business, Government, and the International Economy Unit at the Harvard Business School and is a member of the interdisciplinary Harvard Business School Healthcare Initiative. His work examines the regulation of science-based industries, with an emphasis on comparative risk analysis and the interplay of changing scientific knowledge with business practices in the pharmaceutical and chemical sectors. Dr. Daemmrich has published on pharmaceutical regulation, biotechnology policy and politics, and innovation in industrial chemistry.

Joseph DiMasi, Ph.D., is Director of Economic Analysis at the Tufts Center for the Study of Drug Development at Tufts University. His research is focused on the new drug development and regulatory review processes and the economics of the pharmaceutical industry. Dr. DiMasi presents his work at numerous professional and industry conferences in the United States and abroad and has testified before the U.S. Congress in hearings leading up to the FDA Modernization Act of 1997 and reauthorization of the Prescription Drug User Fee Act.

Henry G. Grabowski, Ph.D., is a faculty member in the Health Sector Management Program Faculty, a Professor of Economics and the Director of the Program in Pharmaceuticals and Health Economics at Duke University. Dr. Grabowski has published numerous studies on the pharmaceutical industry with his principal research involving the economics of the innovation process, business regulation, industrial organization, and developing therapies for Southern countries.

Paul Howard, Ph.D., is a senior fellow and the director of the Manhattan Institute's Center for Medical Progress. He is also the managing editor of MedicalProgressToday.com, a web magazine that chronicles the connections between market-oriented public policies and better access to more innovative health care. He focuses his research on a wide variety of medical policy issues, including medical innovation, FDA reform, and consumer-driven health care.

Daniel P. Petrylak, M.D., is an Associate Professor of Medicine and the Program Director of the Genitourinary Oncology Section in the Division of Hematology/Oncology at the Columbia University Medical Center. Dr. Petrylak has served on the program committee for the annual meetings of the American Urological Association (2003-7) as well as for the American Society of Clinical Oncology (1995-7, 2001-3). He also has served as a committee member for the Devices and Immunologicals section of the Food and Drug Administration Dr. Petrylak was instrumental in the clinical development of docetaxel for prostate cancer, and he chaired one of the trials that supported its approval for prostate cancer by the FDA in 2004. He was also one of the principal investigators on the SPARC trial, an international registration study of satraplatin, an oral chemotherapy agent, for patients who failed on chemotherapeutic regimen for prostate cancer

Tomas J. Philipson, Ph.D., is a professor at the Harris School for Public Policy at the University of Chicago. He is an associate member of the Department of Economics and has been a Senior Lecturer at the Law School. Dr. Philipson's research focus is on health economics. He served in the Bush Administration as the Senior Economic Advisor to the head of the Food and Drug Administration (FDA) during 2003-04, as the Senior Economic Advisor to the head of the Centers for Medicare and Medicaid Services (CMS) in 2004-05 and is currently serving on an eight member health care task force for Senator John McCain's campaign for President of the United States.

Lance K. Stell, Ph.D., FACFE, is the John and Mary West Thatcher Professor of Philosophy, Davidson College, Davidson, NC, where he serves as Director of the Medical Humanities Program. He also holds appointments as Clinical Professor in the Department of Internal Medicine, at Carolinas Medical Center, Charlotte, NC, and as Full Professor (Adjunct), in the Translational Science Institute, at Wake Forest University School of Medicine, Winston-Salem, NC. Dr. Stell is a Fellow and Diplomate in the American College of Forensic Examiners. He consults and serves as an expert witness in criminal and civil cases in which the ethical standards of health care professionals are implicated. He publishes in ethics, medical ethics and philosophy of law. In 2005, the NC Medical Society recognized Dr. Stell's service to the medical profession with the John Huske Anderson award, the highest honor the Medical Society bestows on a non-physician.

E. Fuller Torrey MD is the Executive Director of the Stanley Medical Research Institute (SMRI) in Chevy Chase, Md. and the founder of the Treatment Advocacy Center in Arlington, VA. SMRI funds approximately 50 treatment trials at any given time for schizophrenia and bipolar disorder. Dr. Torrey was educated at Princeton, McGill and Stanford Universities and is the author of 20 books.